BACKGROUND AND PURPOSE: Treating patients with malignant cerebral infarctions remains a major unsolved problem in medicine. Decompressive craniectomy (DC) improves the bleak outlook but is suboptimal. Using a rat model of severe ischemia/reperfusion with very high mortality due to malignant cerebral edema, we tested the hypothesis that blocking of sulfonylurea receptor 1-regulated NC(Ca-ATP) channels with glibenclamide would compare favorably to DC when reperfusion and treatment were begun 6 hours after onset of ischemia. METHODS: Male Wistar rats underwent filament occlusion of the middle cerebral artery to reduce laser Doppler flowmetry perfusion signals by >75%, with filament removal plus treatment 6 hours later. In rats treated with vehicle versus glibenclamide (10 microg/kg IP plus 200 ng/h SC), we compared mortality, neurologic function, and brain swelling at 24 hours. In rats treated with DC versus glibenclamide, we compared neurologic function for 2 weeks and histologic outcomes. RESULTS: Compared with vehicle, glibenclamide treatment reduced 24-hour mortality from 67% to 5% and reduced hemispheric swelling at 24 hours from 21% to 8%. DC eliminated 24-hour mortality, but neurologic function during the next 2 weeks was significantly better with glibenclamide compared with DC. Watershed cortex and deep white matter were significantly better preserved with glibenclamide compared with DC. CONCLUSIONS: In a rat model of severe ischemia/reperfusion, with reperfusion and treatment beginning 6 hours after onset of ischemia, glibenclamide is as effective as DC in preventing death from malignant cerebral edema but is superior to DC in preserving neurologic function and the integrity of watershed cortex and deep white matter.
BACKGROUND AND PURPOSE: Treating patients with malignant cerebral infarctions remains a major unsolved problem in medicine. Decompressive craniectomy (DC) improves the bleak outlook but is suboptimal. Using a rat model of severe ischemia/reperfusion with very high mortality due to malignant cerebral edema, we tested the hypothesis that blocking of sulfonylurea receptor 1-regulated NC(Ca-ATP) channels with glibenclamide would compare favorably to DC when reperfusion and treatment were begun 6 hours after onset of ischemia. METHODS: Male Wistar rats underwent filament occlusion of the middle cerebral artery to reduce laser Doppler flowmetry perfusion signals by >75%, with filament removal plus treatment 6 hours later. In rats treated with vehicle versus glibenclamide (10 microg/kg IP plus 200 ng/h SC), we compared mortality, neurologic function, and brain swelling at 24 hours. In rats treated with DC versus glibenclamide, we compared neurologic function for 2 weeks and histologic outcomes. RESULTS: Compared with vehicle, glibenclamide treatment reduced 24-hour mortality from 67% to 5% and reduced hemispheric swelling at 24 hours from 21% to 8%. DC eliminated 24-hour mortality, but neurologic function during the next 2 weeks was significantly better with glibenclamide compared with DC. Watershed cortex and deep white matter were significantly better preserved with glibenclamide compared with DC. CONCLUSIONS: In a rat model of severe ischemia/reperfusion, with reperfusion and treatment beginning 6 hours after onset of ischemia, glibenclamide is as effective as DC in preventing death from malignant cerebral edema but is superior to DC in preserving neurologic function and the integrity of watershed cortex and deep white matter.
Authors: A Doerfler; M Forsting; W Reith; C Staff; S Heiland; W R Schäbitz; R von Kummer; W Hacke; K Sartor Journal: J Neurosurg Date: 1996-11 Impact factor: 5.115
Authors: J Marc Simard; Juan Sahuquillo; Kevin N Sheth; Kristopher T Kahle; Brian P Walcott Journal: Curr Treat Options Neurol Date: 2011-04 Impact factor: 3.598
Authors: Kevin N Sheth; W Taylor Kimberly; Jordan J Elm; Thomas A Kent; Albert J Yoo; Götz Thomalla; Bruce Campbell; Geoffrey A Donnan; Stephen M Davis; Gregory W Albers; Sven Jacobson; Gregory del Zoppo; J Marc Simard; Barney J Stern; Pitchaiah Mandava Journal: Neurocrit Care Date: 2014-08 Impact factor: 3.210
Authors: Arjun Khanna; Kristopher T Kahle; Brian P Walcott; Volodymyr Gerzanich; J Marc Simard Journal: Transl Stroke Res Date: 2013-11-22 Impact factor: 6.829
Authors: Kevin N Sheth; W Taylor Kimberly; Jordan J Elm; Thomas A Kent; Pitchaiah Mandava; Albert J Yoo; Götz Thomalla; Bruce Campbell; Geoffrey A Donnan; Stephen M Davis; Gregory W Albers; Sven Jacobson; J Marc Simard; Barney J Stern Journal: Stroke Date: 2013-11-05 Impact factor: 7.914
Authors: Hagen Kunte; Markus A Busch; Katrin Trostdorf; Bernd Vollnberg; Lutz Harms; Rupal I Mehta; Rudolf J Castellani; Pitchaiah Mandava; Thomas A Kent; J Marc Simard Journal: Ann Neurol Date: 2012-11 Impact factor: 10.422